Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer

ClinicalTrials.gov ID

NCT07563205

Lead Sponsor

GFPC InvestigationOTHER

Overall Status

Recruiting

Study Type

Observational

Enrollment

100Estimated

Last Update Posted

May 1, 2026Actual

Start Date

Nov 19, 2025Actual

Primary Completion Date

Nov 19, 2027Estimated

Completion Date

Nov 19, 2027Estimated

Official Title

Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer as Part of an Early Access Program

Brief Summary

The purpose of this observational study is to understand how well a treatment combining chemotherapy and amivantamab works in real life, and how safe it is, in adults with metastatic non-small cell lung cancer (NSCLC) who have certain EGFR gene mutations.

The study includes two groups of people:

• Group A: people with an EGFR exon 20 insertion who receive amivantamab together with platinum-based chemotherapy as their first treatment, through an early access program.
• Group B: people with an EGFR exon 19 or exon 21 mutation who receive amivantamab with platinum-based chemotherapy after having been treated with osimertinib (with or without chemotherapy), also through an early access program.

The main question the study wants to answer is:

How long can the combination of amivantamab and chemotherapy keep the cancer from coming back or getting worse in these two groups of people?

People already receiving amivantamab and chemotherapy for NSCLC through an early access program may be included. They will continue to be followed by their usual oncologist as part of their normal medical care. The study will simply collect their medical information from March 21, 2024 to October 21, 2025.

No extra tests or procedures are required. This is an observational study, carried out by the GFPC and partner centers in France.

• Non-Small Cell Lung Cancer
• Non Small Cell Lung Cancer Metastatic
• Non Small Cell Lung Cancer NSCLC
• Non Small Cell Lung Carcinoma
• NSCLC
• EGFR
• EGFR Exon 20 Insertion Mutation
• EGFR Exon 19 Deletion Mutation
• EGFR Exon 21 Mutation

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Patient over 18 years old
• Cohort A: Patient with metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 20 insertion treated with amivantamab-platimum based chemotherapy via an early access program in first line setting.
• Cohort B: Patient with metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 19 or 21 treated with amivantamab-platimum based chemotherapy post osimertinib (with or without chemotherapy) via an early access program.
• Patient covered by the French National Health Insurance system or by an approved third-party payer
• Patient who does not object to the collection of their personal data for research purposes (an information sheet will be provided to all living participants; for deceased participants, documented non-opposition in the medical record is not required)

Exclusion Criteria:

• Patient placed under legal guardianship or subject to a protective legal measure
• Patient who explicitly refuses the collection or use of their personal data for research purposes
• Patient not enrolled, managed, or followed at the investigating site by a qualified site investigator

Observational Model

Cohort

Time Perspective

Other

Lead Sponsor

GFPC InvestigationOTHER

boris.duchemann@aphp.fr

Cdujon@ght78sud.fr

elexis.cortot@chru-lille.fr

p.bombaron@orange.fr

romane.gille@lyon.unicancer.fr

laurent.GREILLIER@ap-hm.fr

sophie.bayle@chu-st-etienne.fr

aurelie.kienlen@chr-reunion.fr

• A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  NCT06667076

  RecruitingInterventionalPhase 2Updated Aug 28, 2026
• A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting

  NCT07230691

  RecruitingObservationalUpdated Aug 28, 2026
• A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

  NCT04538664

  Active, not recruitingInterventionalPhase 3Updated Aug 31, 2026
• A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

  NCT05498428

  RecruitingInterventionalPhase 2Updated Aug 28, 2026
• A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC

  NCT07586202

  RecruitingInterventionalPhase 2Updated Aug 28, 2026
• Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion

  NCT06247826

  RecruitingInterventionalNot ApplicableUpdated Apr 29, 2026